GSK plots big launches in emerging markets

GlaxoSmithKline is preparing to launch its smoking-cessation products in as many as 20 new emerging markets--including China, India and Russia--in another sign of the British drugmaker's desire to build sales in the developing world. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.